Welcome to our dedicated page for Oncology Institute SEC filings (Ticker: TOI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oncology Institute's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oncology Institute's regulatory disclosures and financial reporting.
Starling Oncology, Inc. insider Jorey Chernett, a more-than-10% owner, reported mixed transactions in company securities. On 2026-08-14, Chernett purchased 12,000 shares of common stock at $6.54 per share, bringing direct holdings to 10,660,858 shares. On 2026-08-13, Chernett sold 100 call option contracts on Starling Oncology (each linked to 100 shares, or 10,000 underlying common shares) with a $9.00 exercise price and 19-Feb-2027 expiration, at $6.24 per option. According to a footnote, this option sale is treated as a matchable transaction under Section 16(b), and Chernett intends to disgorge the calculated short-swing profit to the issuer.
Starling Oncology, Inc. reported higher revenue and narrower losses for the three and six months ended June 30, 2026. Total operating revenue reached $161,282 thousand in Q2 and $308,723 thousand year‑to‑date, driven by growth in specialty pharmacy and capitated patient services.
Loss from operations improved to $4,616 thousand in Q2 and $11,129 thousand year‑to‑date, with net loss of $9,789 thousand for the quarter and $12,281 thousand for six months. Operating cash flow turned positive at $9,725 thousand, and cash and equivalents increased to $41,094 thousand. The company remained in a stockholders’ deficit of $24,914 thousand and carried $79,867 thousand of senior secured convertible debt at June 30, 2026, which it repaid in full (approximately $86 million principal) on July 1, 2026.
Starling Oncology, Inc. reported strong Q2 2026 results, with total operating revenue of $161,282 thousand, up from $119,802 thousand a year earlier, and CEO commentary noting revenue grew 35% year over year. Net loss narrowed to $(9,789) thousand and Adjusted EBITDA turned positive at $229 thousand.
For the first six months of 2026, cash provided by operating activities improved to $9,725 thousand from $(15,190) thousand, supporting cash and cash equivalents of $41,094 thousand at June 30, 2026. Management highlighted growth in capitated revenue, which reached $27,974 thousand in Q2, and lives under value-based contracts of 2.1 million.
Reflecting this momentum, the company raised full‑year 2026 guidance, now expecting revenue of $650 to $670 million, gross profit of $105 to $110 million, and Adjusted EBITDA of $2 to $7 million, while reiterating projected Free Cash Flow of $5 to $15 million.
Starling Oncology, Inc., formerly The Oncology Institute, Inc., has changed its corporate name effective July 28, 2026 by filing a Certificate of Amendment in Delaware. Its common stock and warrants continue to trade on Nasdaq, with the common stock ticker changing to STLN.
The company states that the name and symbol changes do not affect stockholder rights and that no stockholder action is required. A related press release explains that the rebrand reflects the evolution into an integrated, value-based oncology platform serving about 2.1 million patients through more than 400 clinicians at over 100 clinics across five states.
Kaushal Mohit reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Kaushal Mohit received a grant of 33,133 restricted stock units (RSUs) of common stock on July 27, 2026. Each RSU entitles him to one share of common stock upon settlement.
The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service with the company on the vesting date. Following this award, his reported direct holdings total 205,716 shares of common stock.
McGeorge Anne reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that director Anne McGeorge received a grant of 41,165 restricted stock units (RSUs) of common stock. Each RSU entitles her to one share upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to her continued service. Following this award, her direct holdings total 332,535 shares of common stock.
Pacala Mark L reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark L. Pacala received an equity award of 30,120 restricted stock units (RSUs), each settling into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service, bringing his direct holdings to 286,881 shares.
STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 31,124 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-27. Each RSU entitles him to receive one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, contingent on his continued service through that date. Following this award, Stolper directly holds 56,957 shares of common stock. The RSUs were granted at a stated price of $0.00 per share, reflecting their nature as a compensation grant rather than a market purchase.
TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director TZOUMAKAS KIMBERLY JO received a grant of 29,116 restricted stock units on July 27, 2026, each entitling her to one share of common stock upon settlement. These RSUs vest in full at the 2027 annual meeting of stockholders, bringing her direct holdings to 46,301 shares.
Hively Brad reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that director Brad Hively received an equity grant of 27,108 shares of common stock on July 27, 2026, structured as restricted stock units (RSUs) at a stated price of $0.0000 per share. Each RSU entitles him to one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to his continued service with the company through that date. Following this award, Hively directly holds 710,829 shares of Oncology Institute common stock.